Expansion Opportunities Aragen has actively expanded its global footprint with facility expansions in Bangalore, India and Hyderabad, India to support tech transfer and manufacturing at improved cost-of-goods-sold (COGS). This suggests a readiness to scale programs for international clients and provide end-to-end development-to-manufacturing support.

CLD Innovation The launch of the RapTr 2022 cell line development platform indicates a focus on accelerated, high-yield lineage creation for complex biologics, presenting a strong cross-sell opportunity for antibody and non-antibody protein programs requiring rapid timelines.

High-Value Capabilities Aragen offers CHO-based expression with high productivity (up to 5 g/L in 5 months) and a royalty-free, milestone-free model, which can be positioned to clients seeking predictable collaboration economics and fast path to candidate generation.

Therapeutic Expertise Deep experience in challenging modalities such as bi- and multi-specific antibodies and non-antibody proteins, coupled with a track record of cell lines producing marketed products, supports upsell into early discovery, lead optimization, and scale-up programs.

Strategic Partnerships Global academic and industry talent, combined with scalable formulation and manufacturing capabilities, positions Aragen as a preferred CRO for long-term programs, enabling cross-sell across discovery, protein production, and translational services to broaden account penetration.